These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14662555)

  • 21. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
    J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indication of an antipsychotic action of the opiate antagonist naloxone.
    Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
    Potkin SG; Litman RE; Torres R; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of diagnosis, hospital and sex on the effects of bromperidol].
    Woggon B; Fleischhauer J; Widmer A
    Int Pharmacopsychiatry; 1979; 14(4):213-27. PubMed ID: 42629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The "delayed onset" of antipsychotic action--an idea whose time has come and gone.
    Agid O; Seeman P; Kapur S
    J Psychiatry Neurosci; 2006 Mar; 31(2):93-100. PubMed ID: 16575424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Open studies in comparison to controlled studies in testing of neuroleptics].
    Pajonk FG; Holzbach R; Naber D
    Fortschr Neurol Psychiatr; 2000 Jul; 68(7):313-20. PubMed ID: 10945157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation.
    Luchins DJ; Dojka DM; Hanrahan P
    Am J Ment Retard; 1993 Jul; 98(1):165-72. PubMed ID: 8103998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
    Bures E; Pöldinger W
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
    [No Abstract]   [Full Text] [Related]  

  • 34. [The use of bromperidol in an open study].
    Hucker H
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():53-61. PubMed ID: 35480
    [No Abstract]   [Full Text] [Related]  

  • 35. Does a four-week delay in the introduction of medication alter the course of functional psychosis?
    Johnstone EC; Owens DG; Crow TJ; Davis JM
    J Psychopharmacol; 1999; 13(3):238-44. PubMed ID: 10512078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mental health nursing. Depot drugs in community psychiatry.
    Thomas B
    Nurs Times; 1984 Jan 18-24; 80(3):43-6. PubMed ID: 6142448
    [No Abstract]   [Full Text] [Related]  

  • 37. [7 years of experience with delayed action neuroleptics].
    Noguera Hosta R; Rendueles de Olmedo G
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1978; 6(3):293-8. PubMed ID: 31066
    [No Abstract]   [Full Text] [Related]  

  • 38. Antipsychotic medications and seizures.
    Marks RC; Luchins DJ
    Psychiatr Med; 1991; 9(1):37-52. PubMed ID: 1673258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Withdrawal of delayed-action neuroleptics in psychotic patients].
    Maillard M; Coutanceau R; Marchina JC
    Ann Med Psychol (Paris); 1979; 137(3-4):351-5. PubMed ID: 40514
    [No Abstract]   [Full Text] [Related]  

  • 40. Antipsychotic medications.
    Harris E
    Am J Nurs; 1981 Jul; 81(7):1316-23. PubMed ID: 6113761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.